Edition:
India

Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

6.37USD
1:18am IST
Change (% chg)

$0.13 (+2.08%)
Prev Close
$6.24
Open
$6.20
Day's High
$7.00
Day's Low
$6.04
Volume
320,687
Avg. Vol
182,340
52-wk High
$25.95
52-wk Low
$5.42

Select another date:

Mon, Aug 14 2017

BRIEF-Zynerba Pharmaceuticals announces results from phase 2 STOP clinical trial

* Zynerba Pharmaceuticals announces that results from phase 2 stop trial support continued development of ZYN002 in osteoarthritis

Zynerba shares plunge as cannabis-based epilepsy gel fails study

Zynerba Pharmaceuticals Inc's stock lost more than half its value on Monday after the U.S. drug developer said its synthetic cannabis-based gel for epilepsy failed a mid-stage study.

UPDATE 2-Zynerba shares plunge as cannabis-based epilepsy gel fails study

* ZYNE stock sinks about 60 pct, GW shares rise 4 pct (Adds analysts' comments, conf. call details, GW shares; updates ZYNE shares)

Zynerba's cannabis-based gel for epilepsy fails study

Aug 7 Zynerba Pharmaceuticals said on Monday its experimental synthetic cannabis-based gel failed to induce a statistically significant reduction in seizures in a mid-stage study involving epilepsy patients.

BRIEF-Zynerba Pharma announces top-line results from phase 2 star 1 trial of ZYN002

* Zynerba Pharmaceuticals announces top-line results from phase 2 star 1 trial of ZYN002 in adult epilepsy patients with focal seizures

BRIEF-Zynerba Pharmaceuticals reports second quarter 2017 results

* Zynerba Pharmaceuticals reports second quarter 2017 financial results and operational highlights

BRIEF-Zynerba Pharmaceuticals initiates ZYN001 phase 1 clinical program

* Zynerba Pharmaceuticals initiates ZYN001 phase 1 clinical program

BRIEF-Zynerba Pharma achieves target enrollment in exploratory phase 2 trial of ZYN002 in fragile X syndrome

* Zynerba Pharmaceuticals achieves target enrollment in exploratory phase 2 trial of ZYN002 in fragile X syndrome Source text for Eikon: Further company coverage:

BRIEF-Zynerba Pharmaceuticals reports Q1 loss per share $0.60

* Zynerba Pharmaceuticals reports first quarter 2017 financial results and operational highlights

BRIEF-Zynerba Pharmaceuticals qtrly loss per share $0.71

* Zynerba - top-line results from fab-c exploratory phase 2 clinical trial in pediatric patients with fragile x syndrome expected in q3 of 2017

Select another date: